Clinical trial · Observational
Treatments for Brain Metastases With Poor Prognostic Factors
Effects of Local and Systemic Treatments in Brain Metastases With Poor Prognostic Factors: Multicenter Retrospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn about treatments in brain metastases with poor prognostic factors. The main questions it aims to answer are: * What kind of local treatment provides a survival benefit for patients with poor prognostic factors? * What kind of systemic treatment provides a survival benefit for patients with poor prognostic factors? * Will the combination of local treatment and systemic treatment provide a survival benefit for patients with poor prognostic factors? Participants will be asked to provide personal information about their living status, symptoms, and disease control during the follow-up.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| neurosurgical resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- label
- local treatment group vs non-local treatment group
- description
- Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group or otherwise into non-local treatment group
- interventionNames
- Procedure: neurosurgical resection
- label
- systemic treatment group vs non-systemic treatment group
- description
- Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group or otherwise into non-systemic treatment group
- label
- local treatment group vs systemic treatment group
- description
- Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Evidence of pathological diagnosis of primary tumor; 2. Brain metastases confirmed by enhanced magnetic resonance imaging; 3. Complete clinical information Exclusion Criteria: 1. Survival time less than 30 days; 2. If surgical treatment is accepted, the surgical treatment is not tumor resection, but ventricle puncture, biopsy and other non-tumor reducing surgery; 3. Incomplete clinical data; 4. Patients with 2 or more types of tumors.
References
Publications (1)
- DERIVEDLi A, Feng D, Liu C, Huang C, Li T, Wei D, Wei F, Shen M, Qin C, Deng S, Liang H, Mo P, Dong M, Yu Y, Liang L. Prognostic Analysis of Lung Cancer With Brain Metastases in Elderly Patients: A Multicenter Retrospective Study. Aging Med (Milton). 2025 Dec 31;8(6):585-591. doi: 10.1002/agm2.70060. eCollection 2025 Dec. PMID 41531790